论文部分内容阅读
目的：探讨硫糖铝新三联疗法治疗幽门螺杆菌（ＨＰ）阳性十二指肠溃疡的疗效和安全性。方法：将ＨＰ阳性十二指肠溃疡患者随机分为３组；Ａ组（ｎ＝４５）和Ｂ组（ｎ＝４２）分别接受硫糖铝＋呋喃唑酮＋兰索拉唑和胶体铋剂＋阿莫西林＋甲硝吐治疗，Ｃ组（ｎ＝４３）接受呋喃唑酮＋兰索拉唑治疗，疗程均为２周。停药４周后复查胃镜，了解ＨＰ根除率和溃疡愈合率，并随访１年。结果：停药４周后Ａ组、Ｂ组、Ｃ组ＨＰ根除率和溃疡愈合率分别为８５．３％、８２．２％、６１．２％和８６．７％、８３．３％、６５．１％，Ａ组、Ｂ组与 Ｃ组比较均有显著差异（ Ｐ＜０． ０５），但 Ａ组无明显副作用。随访 １年，Ａ组、Ｂ组和 Ｃ组溃疡复发率分别为 １４． ３％、１８． ４％和５３．９％。进一步分析发现溃疡复发率和胃窦炎症好转率均与ＨＰ根除率密切相关。结论：新三联疗法治疗ＨＰ阳性十二指肠溃疡，具有较高疗效、安全、耐受性好的优点。
Objective: To investigate the efficacy and safety of sucralfate triple therapy in the treatment of Helicobacter pylori (HP) -positive duodenal ulcer. Methods: The patients with HP-positive duodenal ulcer were randomly divided into 3 groups: group A (n = 45) and group B (n = 42) received sucralfate + furazolidone + lansoprazole and colloidal bismuth + Moxilin + metronidazole spit treatment, C group (n = 43) received furazolidone + lansoprazole treatment, the course of treatment were 2 weeks. Four weeks after discontinuation of gastroscopy review, understand the HP eradication rate and ulcer healing, and follow-up of 1 year. Results: After 4 weeks of treatment, the eradication rates of HP and the ulcer in groups A, B and C were 85.3%, 82.2%, 61.2% and 86.7%, 83.3% and 65%, respectively .1%, A group, B group and C group were significantly different (P <0.05), but no significant side effects in group A. The follow-up of 1 year, group A, B and C group ulcer recurrence rates were 14. 3%, 18. 4% and 53.9%. Further analysis found that the rate of ulcer recurrence and gastric antral inflammation are closely related to the rate of HP eradication. Conclusion: The new triple therapy for HP-positive duodenal ulcer, with high efficacy, safety, good tolerance advantages.